CRISPR Therapeutics AGCRSP +1.71%41 Current Ratio is 17.96 as of Mar. 2026, which is 7% above its 10-year median of 16.84. GuruFocus rates CRSP with a GF Score™ of 41/100 and a GF Value™ of $2.44 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,412 Biotechnology companies, CRISPR Therapeutics AG ranks better than 90.08% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. CRISPR Therapeutics AG's current ratio for the quarter that ended in Mar. 2026 was 17.96.
CRISPR Therapeutics AG has a current ratio of 17.96. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for CRISPR Therapeutics AG's Current Ratio or its related term are showing as below:
CRSP'
s Current Ratio Range Over the Past 10 Years
Min: 2.97 Med: 16.84 Max: 26.23
Current: 17.96
During the past 12 years, CRISPR Therapeutics AG's highest Current Ratio was 26.23. The lowest was 2.97. And the median was 16.84.
CRSP's Current Ratio is ranked better than 90.08% of 1412
companies
in the Biotechnology industry
Industry Median: 3.89
vs CRSP: 17.96
CRISPR Therapeutics AG (NAS:CRSP) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
CRISPR Therapeutics AG Current Ratio Related Terms
CRISPR Therapeutics AG Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRSP vs ORKA, TVTX, MANE: Current Ratio Comparison
For the Biotechnology subindustry, CRISPR Therapeutics AG's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CRISPR Therapeutics AG Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Current Ratio distribution charts can be found below:
* The bar in red indicates where CRISPR Therapeutics AG's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRISPR Therapeutics AG (CRSP) has a Current Ratio of 17.96 as of Mar. 2026. This is near median its historical median of 16.84. Over the past decade, CRISPR Therapeutics AG's Current Ratio has ranged from 2.97 to 26.23. According to the industry distribution chart, CRISPR Therapeutics AG ranks #140 out of 1412 companies in the Biotechnology industry, placing it in the top 9.9%.
Is CRISPR Therapeutics AG's Current Ratio too high?
CRISPR Therapeutics AG's current Current Ratio of 17.96 is near median its 10-year median of 16.84. Over the past 10 years, this metric has ranged from a low of 2.97 to a high of 26.23. The Biotechnology industry median Current Ratio is 3.89. CRISPR Therapeutics AG's value of 17.96 is 361.7% above this industry median. Based on the distribution chart, CRISPR Therapeutics AG ranks #140 out of 1412 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CRISPR Therapeutics AG has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Current Ratio compare to ORKA and TVTX?
According to the Biotechnology industry distribution chart, CRISPR Therapeutics AG ranks #140 out of 1412 companies for Current Ratio. This places CRISPR Therapeutics AG in the top 10% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. CRISPR Therapeutics AG's value of 17.96 is 361.7% above this benchmark. Historically, CRISPR Therapeutics AG's own Current Ratio has ranged from 2.97 to 26.23 over the past decade. While the company's 10-year median is 16.84 vs. the industry median of 3.89, CRISPR Therapeutics AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CRISPR Therapeutics AG's current Current Ratio of 17.96 is 361.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CRISPR Therapeutics AG's current Current Ratio is 17.96, which is near median its own 10-year median of 16.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (CRSP) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.44, compared to a current price of $55.86 — trading 2189.4% above its estimated fair value. The current Current Ratio is 17.96, which is near median its 10-year median of 16.84 and 361.7% above the Biotechnology industry median of 3.89. CRISPR Therapeutics AG's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For CRISPR Therapeutics AG (CRSP), the current Current Ratio is 17.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CRISPR Therapeutics AG (CRSP) Overvalued in 2026?
Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued.
The current stock price of $55.86 is trading 2189.4% above its estimated GF Value™ of $2.44.
GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.
Key valuation signals for CRSP:
Current Ratio: 17.96 (near median its 10-year median of 16.84)
GF Value™: $2.44 vs. price of $55.86 (2189.4% above fair value)
Industry Position: 361.7% above the Biotechnology median (#140 of 1412)
No single metric tells the full story. See the CRSP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
41GF Score
Get the complete analysis for CRSP
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRSP has been successfully added to your 
